Buy Stocks Easy | About Us
August 2, 2021
Buy Stocks Easy | Online Stocks

XBIT


Buy XBiotech Inc. Stock (symbol: XBIT) Easy Online

Company Name: XBiotech Inc.

Symbol: XBIT

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2015

XBIT Current Share Price

Today's XBIT ( XBiotech Inc. ) opening price: $19.6100

Yesterday's XBIT ( XBiotech Inc. ) closing price: $19.4700

XBiotech Inc. Stock ( symbol: XBIT ) Price Chart since IPO (2015):

12 Months XBiotech Inc. Stock ( symbol: XBIT ) Price Chart

Popular Questions about XBiotech Inc. Public Stock ( XBIT )

A: XBiotech Inc. stock symbol (also called stock or share ticker) is XBIT

A: XBiotech Inc. IPO (Initial Public Offering) took place on 2015

A: XBiotech Inc.'s stock (XBIT symbol) price at ther IPO (initial Public Offering) was $19.6100

Q: Is XBIT stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'XBiotech Inc. stock (symbol: XBIT) at the beginning of 2019, at the opening share price of $6.6000, with a minimum of $200, by now your shares would be worth $6260 and your profit would be $6060 - SHOW ONLY IF PROFIT.

Buy XBiotech Inc. Stock Easy Online

XBiotech Inc. Stock Ticker Price Chart since IPO:





XBiotech Inc. Stock Price Yesterday



 


XBiotech Inc. Stock Price – Last Week




 


XBiotech Inc. Stock Price – Last Month




 


XBiotech Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            https://seekingalpha.com/article/4312921-xbiotech-move-to-out-licence-next-generation-antibody-brings-in-substantial-cash-for-pipeline
                            

                                
XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion

                                
                                
XBiotech Move To Out-Licence Next Generation Antibody Brings In Sub...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/17/1961550/0/en/XBiotech-Added-to-NASDAQ-Biotechnology-Index.html
                            

                                
XBiotech Added to NASDAQ Biotechnology Index

                                
                                
AUSTIN, Texas, Dec.  17, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (N...


                            

                        
                    

                


                            

                    


                        
                            https://www.fool.com/investing/2019/12/09/this-small-cap-biotech-gained-as-much-as-1064-toda.aspx
                            

                                
This Small-Cap Biotech Gained as Much as 106.4% Today

                                
                                
XBiotech announced a massive deal with Johnson & Johnson subsidiary...


                            

                        
                    

                


                            

                    


                        
                            https://247wallst.com/healthcare-business/2019/12/09/why-these-3-biotechs-more-than-doubled-on-monday/
                            

                                
Why These 3 Biotechs More Than Doubled on Monday

                                
                                
Monday was a breakout day for a few biotech companies. Some made ab...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/07/1957519/0/en/XBiotech-Announces-Agreement-to-Sell-True-Human-Antibody-Bermekimab-Targeting-IL-1a-to-Janssen.html
                            

                                
XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

                                
                                
XBiotech will continue its True Human anti IL-1? antibody discovery...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/19/1949455/0/en/XBiotech-Announces-Rapid-Enrollment-for-its-Randomized-Multi-Center-Clinical-Study-for-Bermekimab-in-Patients-with-Hidradenitis-Suppurativa.html
                            

                                
XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa

                                
                                
Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/12/1945406/0/en/XBiotech-Announces-First-Patient-Enrolled-in-Placebo-Controlled-Clinical-Study-Evaluating-Its-anti-IL-1-Therapy-Bermekimab-in-Patients-with-Atopic-Dermatitis-Eczema.html
                            

                                
XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1? Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)

                                
                                
AUSTIN, Texas, Nov.  12, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (N...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/23/1934071/0/en/XBiotech-Announces-First-Patient-Enrolled-in-Randomized-Multi-Center-Clinical-Study-Evaluating-Bermekimab-Therapy-in-Patients-with-Hidradenitis-Suppurativa.html
                            

                                
XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

                                
                                
AUSTIN, Texas, Oct.  23, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (N...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924102/0/en/XBiotech-Announces-First-Patient-in-Clinical-Study-to-Evaluate-Bermekimab-in-Systemic-Sclerosis.html
                            

                                
XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis

                                
                                
Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/27/1921818/0/en/XBiotech-Announces-Oral-Presentation-of-Atopic-Dermatitis-Results-for-Bermekimab-at-2019-EADV-Congress-in-Madrid-Spain.html
                            

                                
XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain

                                
                                
Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.